董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Myron Holubiak | 男 | Director and Executive Vice-Chairman | 78 | 250.61万美元 | 22.53 | 2026-02-13 |
| Leonard Mazur | 男 | Chief Executive Officer,Director,Executive Chairman and Secretary | 80 | 450.79万美元 | 73.04 | 2026-02-13 |
| Suren Dutia | 男 | Independent Director | 83 | 72.97万美元 | 2.00 | 2026-02-13 |
| Carol Webb | 女 | Independent Director | 79 | 70.74万美元 | 2.10 | 2026-02-13 |
| Eugene Holuka | 男 | Independent Director | 66 | 71.07万美元 | 2.06 | 2026-02-13 |
| Dennis M. McGrath | 男 | Independent Director | 68 | 71.67万美元 | 1.10 | 2026-02-13 |
| Robert J. Smith | 男 | Independent Director | 65 | 68.15万美元 | 0.80 | 2026-02-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Myron Holubiak | 男 | Director and Executive Vice-Chairman | 78 | 250.61万美元 | 22.53 | 2026-02-13 |
| Leonard Mazur | 男 | Chief Executive Officer,Director,Executive Chairman and Secretary | 80 | 450.79万美元 | 73.04 | 2026-02-13 |
| Jaime Bartushak | 男 | Chief Financial Officer and Chief Business Officer | 58 | 173.35万美元 | 5.78 | 2026-02-13 |
| Myron S. Czuczman | 男 | Chief Medical Officer and Executive Vice President | 66 | 246.15万美元 | 5.60 | 2026-02-13 |
董事简历
中英对照 | 中文 | 英文- Myron Holubiak
-
Myron Holubiak现任公司秘书和董事会成员，自2024年8月12日起担任该职位。在此之前，他曾担任Citius Oncology Sub，Inc.的秘书和董事，自2022年4月1日开始。Holubiak先生还是Citius Pharma的执行副主席，自2022年5月起担任该职位。他还自2015年10月起担任Citius Pharma董事会成员。从2015年10月到2022年4月，Holubiak先生担任Citius Pharma总裁兼首席执行官。Holubiak先生还担任该公司控股多数的子公司NoveCite的代理首席执行官。Holubiak先生在管理大型和新兴的制药和生命科学公司并为其提供咨询方面拥有丰富的经验。Holubiak先生于1998年12月至2001年8月担任罗氏制药公司（“罗氏”）总裁，该公司是一家以研究为基础的大型制药公司。在此之前，他在19年任期内曾在罗氏担任销售和营销职位。自2002年9月至2016年7月，Holubiak先生在董事会任职，最近两年担任BioScrip，Inc.（“BioScrip”）（纳斯达克：BIOS）的董事会主席。BioScrip是全国领先的输液和家庭护理管理解决方案提供商。自2010年7月起，Holubiak先生担任Assembly Biosciences, Inc.（“Assembly”）（纳斯达克：ASMB）及其前身Ventrus Biosciences，Inc.的董事会成员。Assembly是一家生物制药公司，开发针对乙型肝炎病毒（HBV）、三角型肝炎病毒（HDV）和疱疹病毒感染的创新小分子疗法。此外，Holubiak先生还担任私人控股公司bioAffinity技术公司的董事。2013年3月，Holubiak先生创立了公司的全资子公司LMB，并担任LMB的首席执行官兼总裁至2016年3月。此外，Holubiak先生还在2013年4月至2015年4月期间担任管理式护理学院药房基金会的受托人。Holubiak先生获得了匹兹堡大学的分子生物学和生物物理学学士学位；他接受了哈佛商学院和伦敦大学的高级商业培训；以及约克大学健康经济学中心的健康经济学高级培训。
Myron Holubiak is the current Secretary of the Company and a member of the Board of Directors, a position he has held since August 12, 2024. Prior thereto, he served as Secretary and a director of Citius Oncology Sub, Inc., beginning on April 1, 2022. Mr. Holubiak is also the Executive Vice Chairman of Citius Pharma, a position he has held since May 2022. He has also served as a member of the board of directors of Citius Pharma since October 2015. From October 2015 through April 2022, Mr. Holubiak served as Citius Pharma's President and Chief Executive Officer. Mr. Holubiak also serves as the acting Chief Executive Officer of the company's majority owned subsidiary, NoveCite. Mr. Holubiak has extensive experience in managing and advising large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was the President of Roche Laboratories, Inc. ("Roche"), a major research based pharmaceutical company, from December 1998 to August 2001. Prior to that, he held sales and marketing positions at Roche during his 19 year tenure. From September 2002 to July 2016, Mr. Holubiak served on the board of directors and for the last two years was the Chairman of the board of directors of BioScrip, Inc. ("BioScrip") (Nasdaq: BIOS). BioScrip is a leading national provider of infusion and home care management solutions. Since July 2010, Mr. Holubiak has served as a member of the board of directors of Assembly Biosciences, Inc. ("Assembly") (Nasdaq: ASMB) and its predecessor Ventrus Biosciences, Inc. Assembly is a biopharmaceutical company developing innovative, small molecule therapeutics for hepatitis B virus (HBV), hepatitis delta virus (HDV) and herpes virus infections. Additionally, Mr. Holubiak serves as a director for bioAffinity Technologies Inc., a privately held company. In March 2013, Mr. Holubiak founded LMB, the Company's wholly owned subsidiary, and he served as the Chief Executive Officer and President of LMB until March 2016. In addition, Mr. Holubiak was also a trustee of the Academy of Managed Care Pharmacy Foundation from April 2013 to April 2015. Mr. Holubiak received a B.S. in Molecular Biology and Biophysics from the University of Pittsburgh; he received advanced business training from the Harvard Business School and the University of London; and advanced training in health economics from the University of York's Centre for Health Economics. - Myron Holubiak现任公司秘书和董事会成员，自2024年8月12日起担任该职位。在此之前，他曾担任Citius Oncology Sub，Inc.的秘书和董事，自2022年4月1日开始。Holubiak先生还是Citius Pharma的执行副主席，自2022年5月起担任该职位。他还自2015年10月起担任Citius Pharma董事会成员。从2015年10月到2022年4月，Holubiak先生担任Citius Pharma总裁兼首席执行官。Holubiak先生还担任该公司控股多数的子公司NoveCite的代理首席执行官。Holubiak先生在管理大型和新兴的制药和生命科学公司并为其提供咨询方面拥有丰富的经验。Holubiak先生于1998年12月至2001年8月担任罗氏制药公司（“罗氏”）总裁，该公司是一家以研究为基础的大型制药公司。在此之前，他在19年任期内曾在罗氏担任销售和营销职位。自2002年9月至2016年7月，Holubiak先生在董事会任职，最近两年担任BioScrip，Inc.（“BioScrip”）（纳斯达克：BIOS）的董事会主席。BioScrip是全国领先的输液和家庭护理管理解决方案提供商。自2010年7月起，Holubiak先生担任Assembly Biosciences, Inc.（“Assembly”）（纳斯达克：ASMB）及其前身Ventrus Biosciences，Inc.的董事会成员。Assembly是一家生物制药公司，开发针对乙型肝炎病毒（HBV）、三角型肝炎病毒（HDV）和疱疹病毒感染的创新小分子疗法。此外，Holubiak先生还担任私人控股公司bioAffinity技术公司的董事。2013年3月，Holubiak先生创立了公司的全资子公司LMB，并担任LMB的首席执行官兼总裁至2016年3月。此外，Holubiak先生还在2013年4月至2015年4月期间担任管理式护理学院药房基金会的受托人。Holubiak先生获得了匹兹堡大学的分子生物学和生物物理学学士学位；他接受了哈佛商学院和伦敦大学的高级商业培训；以及约克大学健康经济学中心的健康经济学高级培训。
- Myron Holubiak is the current Secretary of the Company and a member of the Board of Directors, a position he has held since August 12, 2024. Prior thereto, he served as Secretary and a director of Citius Oncology Sub, Inc., beginning on April 1, 2022. Mr. Holubiak is also the Executive Vice Chairman of Citius Pharma, a position he has held since May 2022. He has also served as a member of the board of directors of Citius Pharma since October 2015. From October 2015 through April 2022, Mr. Holubiak served as Citius Pharma's President and Chief Executive Officer. Mr. Holubiak also serves as the acting Chief Executive Officer of the company's majority owned subsidiary, NoveCite. Mr. Holubiak has extensive experience in managing and advising large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was the President of Roche Laboratories, Inc. ("Roche"), a major research based pharmaceutical company, from December 1998 to August 2001. Prior to that, he held sales and marketing positions at Roche during his 19 year tenure. From September 2002 to July 2016, Mr. Holubiak served on the board of directors and for the last two years was the Chairman of the board of directors of BioScrip, Inc. ("BioScrip") (Nasdaq: BIOS). BioScrip is a leading national provider of infusion and home care management solutions. Since July 2010, Mr. Holubiak has served as a member of the board of directors of Assembly Biosciences, Inc. ("Assembly") (Nasdaq: ASMB) and its predecessor Ventrus Biosciences, Inc. Assembly is a biopharmaceutical company developing innovative, small molecule therapeutics for hepatitis B virus (HBV), hepatitis delta virus (HDV) and herpes virus infections. Additionally, Mr. Holubiak serves as a director for bioAffinity Technologies Inc., a privately held company. In March 2013, Mr. Holubiak founded LMB, the Company's wholly owned subsidiary, and he served as the Chief Executive Officer and President of LMB until March 2016. In addition, Mr. Holubiak was also a trustee of the Academy of Managed Care Pharmacy Foundation from April 2013 to April 2015. Mr. Holubiak received a B.S. in Molecular Biology and Biophysics from the University of Pittsburgh; he received advanced business training from the Harvard Business School and the University of London; and advanced training in health economics from the University of York's Centre for Health Economics.
- Leonard Mazur
-
Leonard Mazur为公司董事长兼首席执行官，自2024年8月12日起担任该职务。在此之前，他曾担任Citius Oncology Sub，Inc.的首席执行官，自2022年4月1日开始。Mazur先生还担任Citius Pharmaceuticals, Inc.（“Citius Pharmaceuticals”）（纳斯达克：CTXR）的执行主席和秘书，并自2014年9月起担任Citius Pharma的董事会成员。2022年5月，Mazur先生成为Citius Pharma的首席执行官。他还担任Citius Pharma的多数股权子公司NoveCite，Inc.（“NoveCite”）的秘书，并为Citius Pharma和NoveCite提供其他指导。自2021年8月起，Mazur先生担任Hillstream BioPharma，Inc.（纳斯达克：HILS）的董事会成员。Mazur先生是Akrimax Pharmaceuticals，LLC（“Akrimax”）的联合创始人和副主席，该公司是一家私营制药公司，专门生产心血管和普通医药产品。Akrimax成立于2008年9月，在收购各大药企药品的同时，成功推出了处方药。2005年1月至2012年5月，Mazur co先生创立并担任Triax Pharmaceuticals LLC（“Triax”）的首席运营官，这是一家生产处方皮肤病药物的专业制药公司。在加入Triax之前，他是Genesis Pharmaceutical，Inc.（“Genesis”）的创始人，并在1995年至2005年期间担任首席执行官。Genesis Pharmaceutical，Inc.（“Genesis”）是一家皮肤病产品公司，通过皮肤科医生办公室营销其产品，并为主要制药公司共同推广产品。2003年，Mazur先生成功地将Genesis出售给了领先的制药公司Pierre Fabre。Mazur先生在麦蒂斯制药担任执行副总裁、ICN Pharmaceuticals，Inc.担任销售与营销副总裁、Knoll Pharma（巴斯夫的一个部门）和Cooper Laboratories，Inc.期间拥有丰富的销售、营销和业务发展经验。Mazur先生是Manor College的董事会成员，是埃利斯岛荣誉勋章的获得者，之前曾是公司的全资子公司Leonard Meron Biosciences，Inc.（“LMB”）的董事会主席。马祖尔先生在天普大学获得了学士和工商管理硕士学位，并曾在美国海军陆战队预备队服役。
Leonard Mazur is the Chairman and Chief Executive Officer of the Company, a position he has held since August 12, 2024. Prior thereto, he served as the Chief Executive Officer of Citius Oncology Sub, Inc., beginning on April 1, 2022. Mr. Mazur also serves as the Executive Chairman and Secretary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR) and has been a member of the board of directors of Citius Pharma since September 2014. In May 2022, Mr. Mazur became the Chief Executive Officer of Citius Pharma. He also serves as the Secretary of Citius Pharma's majority owned subsidiary, NoveCite, Inc. ("NoveCite"), and provides other guidance to Citius Pharma and NoveCite. Since August 2021, Mr. Mazur has served on the board of directors of Hillstream BioPharma, Inc. (Nasdaq: HILS). Mr. Mazur is the co founder and Vice Chairman of Akrimax Pharmaceuticals, LLC ("Akrimax"), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Akrimax was founded in September 2008 and has successfully launched prescription drugs while acquiring drugs from major pharmaceutical companies. From January 2005 to May 2012, Mr. Mazur co founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC ("Triax"), a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder and, from 1995 to 2005, Chief Executive Officer of Genesis Pharmaceutical, Inc. ("Genesis"), a dermatological products company that marketed its products through dermatologists' offices as well as co promoting products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company. Mr. Mazur has extensive sales, marketing and business development experience from his tenures at Medicis Pharmaceutical Corporation as Executive Vice President, ICN Pharmaceuticals, Inc. as Vice President, Sales & Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc. Mr. Mazur is a member of the Board of Trustees of Manor College, is a recipient of the Ellis Island Medal of Honor and was previously the Chairman of the board of directors of Leonard Meron Biosciences, Inc. ("LMB"), the Company's wholly owned subsidiary. Mr. Mazur received both his B.A. and M.B.A. from Temple University and has served in the U.S. Marine Corps Reserves. - Leonard Mazur为公司董事长兼首席执行官，自2024年8月12日起担任该职务。在此之前，他曾担任Citius Oncology Sub，Inc.的首席执行官，自2022年4月1日开始。Mazur先生还担任Citius Pharmaceuticals, Inc.（“Citius Pharmaceuticals”）（纳斯达克：CTXR）的执行主席和秘书，并自2014年9月起担任Citius Pharma的董事会成员。2022年5月，Mazur先生成为Citius Pharma的首席执行官。他还担任Citius Pharma的多数股权子公司NoveCite，Inc.（“NoveCite”）的秘书，并为Citius Pharma和NoveCite提供其他指导。自2021年8月起，Mazur先生担任Hillstream BioPharma，Inc.（纳斯达克：HILS）的董事会成员。Mazur先生是Akrimax Pharmaceuticals，LLC（“Akrimax”）的联合创始人和副主席，该公司是一家私营制药公司，专门生产心血管和普通医药产品。Akrimax成立于2008年9月，在收购各大药企药品的同时，成功推出了处方药。2005年1月至2012年5月，Mazur co先生创立并担任Triax Pharmaceuticals LLC（“Triax”）的首席运营官，这是一家生产处方皮肤病药物的专业制药公司。在加入Triax之前，他是Genesis Pharmaceutical，Inc.（“Genesis”）的创始人，并在1995年至2005年期间担任首席执行官。Genesis Pharmaceutical，Inc.（“Genesis”）是一家皮肤病产品公司，通过皮肤科医生办公室营销其产品，并为主要制药公司共同推广产品。2003年，Mazur先生成功地将Genesis出售给了领先的制药公司Pierre Fabre。Mazur先生在麦蒂斯制药担任执行副总裁、ICN Pharmaceuticals，Inc.担任销售与营销副总裁、Knoll Pharma（巴斯夫的一个部门）和Cooper Laboratories，Inc.期间拥有丰富的销售、营销和业务发展经验。Mazur先生是Manor College的董事会成员，是埃利斯岛荣誉勋章的获得者，之前曾是公司的全资子公司Leonard Meron Biosciences，Inc.（“LMB”）的董事会主席。马祖尔先生在天普大学获得了学士和工商管理硕士学位，并曾在美国海军陆战队预备队服役。
- Leonard Mazur is the Chairman and Chief Executive Officer of the Company, a position he has held since August 12, 2024. Prior thereto, he served as the Chief Executive Officer of Citius Oncology Sub, Inc., beginning on April 1, 2022. Mr. Mazur also serves as the Executive Chairman and Secretary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR) and has been a member of the board of directors of Citius Pharma since September 2014. In May 2022, Mr. Mazur became the Chief Executive Officer of Citius Pharma. He also serves as the Secretary of Citius Pharma's majority owned subsidiary, NoveCite, Inc. ("NoveCite"), and provides other guidance to Citius Pharma and NoveCite. Since August 2021, Mr. Mazur has served on the board of directors of Hillstream BioPharma, Inc. (Nasdaq: HILS). Mr. Mazur is the co founder and Vice Chairman of Akrimax Pharmaceuticals, LLC ("Akrimax"), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Akrimax was founded in September 2008 and has successfully launched prescription drugs while acquiring drugs from major pharmaceutical companies. From January 2005 to May 2012, Mr. Mazur co founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC ("Triax"), a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder and, from 1995 to 2005, Chief Executive Officer of Genesis Pharmaceutical, Inc. ("Genesis"), a dermatological products company that marketed its products through dermatologists' offices as well as co promoting products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company. Mr. Mazur has extensive sales, marketing and business development experience from his tenures at Medicis Pharmaceutical Corporation as Executive Vice President, ICN Pharmaceuticals, Inc. as Vice President, Sales & Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc. Mr. Mazur is a member of the Board of Trustees of Manor College, is a recipient of the Ellis Island Medal of Honor and was previously the Chairman of the board of directors of Leonard Meron Biosciences, Inc. ("LMB"), the Company's wholly owned subsidiary. Mr. Mazur received both his B.A. and M.B.A. from Temple University and has served in the U.S. Marine Corps Reserves.
- Suren Dutia
-
Suren Dutia自2024年8月12日起担任董事会成员。Dutia先生还自2015年10月起担任Citius Pharma董事会成员。除了担任Citius Pharma的外部独立董事外，Dutia先生自2016年以来一直担任Flint Rehab和Vahan Inc的董事。Dutia先生参与培养企业家精神已有20多年，曾于2011年3月至2016年12月担任尤因马里奥·考夫曼基金会高级研究员，并于2010年至2013年担任圣路易斯华盛顿大学斯坎达拉里斯创业与创新中心高级研究员。他自2012年5月起担任加州大学欧文分校数字化转型中心顾问委员会成员。2006年2月至2010年5月，Dutia先生担任TiE的首席执行官，TiE是一家参与在全球范围内培养企业家精神的非营利组织。2011年2月至2013年5月，Dutia先生担任LifeProof的董事，并于2000年7月至2011年12月担任Anvita Health的董事。1989年至1998年，Dutia先生担任XScribe Corporation的首席执行官和董事会主席。在Xscribe Corporation任职之前，Dutia先生曾在Dynatech Corporation担任多个职位，此外，他还是一家医疗仪器公司的总裁。Dutia先生在圣路易斯华盛顿大学获得化学工程学士和硕士学位以及政治学学士学位。此外，他还获得了达拉斯大学的工商管理硕士学位。
Suren Dutia has been a member of the Board of Directors since August 12, 2024. Mr. Dutia has also been a member of the board of directors of Citius Pharma since October 2015. In addition to his role as an outside independent director of Citius Pharma, Mr. Dutia has been serving as director of Flint Rehab and Vahan Inc, since 2016. Mr. Dutia has been involved in fostering entrepreneurship for more than 20 years and served as Senior Fellow of the Ewing Mario Kauffman Foundation from March 2011 to December 2016 and Senior Fellow of Skandalaris Center for Entrepreneurship and Innovation at Washington University, St. Louis from 2010 to 2013. He has served as a member of the advisory board of Center for Digital Transformation, University of California, Irvine since May 2012. From February 2006 to May 2010, Mr. Dutia served as the Chief Executive Officer of TiE, a non profit organization involved in fostering entrepreneurship globally. From February 2011 to May 2013, Mr. Dutia served as a director of LifeProof and from July 2000 to December 2011, he served as a director of Anvita Health. From 1989 to 1998, Mr. Dutia served as the Chief Executive Officer and Chairman of the board of directors of Xscribe Corporation. Prior to his positions with Xscribe Corporation, Mr. Dutia held several positions with Dynatech Corporation, and, in addition, he was the President of a medical instruments company. Mr. Dutia received his B.S. and M.S. degrees in chemical engineering and B.A. in political science from Washington University, St. Louis. In addition, he obtained an M.B.A. from the University of Dallas. - Suren Dutia自2024年8月12日起担任董事会成员。Dutia先生还自2015年10月起担任Citius Pharma董事会成员。除了担任Citius Pharma的外部独立董事外，Dutia先生自2016年以来一直担任Flint Rehab和Vahan Inc的董事。Dutia先生参与培养企业家精神已有20多年，曾于2011年3月至2016年12月担任尤因马里奥·考夫曼基金会高级研究员，并于2010年至2013年担任圣路易斯华盛顿大学斯坎达拉里斯创业与创新中心高级研究员。他自2012年5月起担任加州大学欧文分校数字化转型中心顾问委员会成员。2006年2月至2010年5月，Dutia先生担任TiE的首席执行官，TiE是一家参与在全球范围内培养企业家精神的非营利组织。2011年2月至2013年5月，Dutia先生担任LifeProof的董事，并于2000年7月至2011年12月担任Anvita Health的董事。1989年至1998年，Dutia先生担任XScribe Corporation的首席执行官和董事会主席。在Xscribe Corporation任职之前，Dutia先生曾在Dynatech Corporation担任多个职位，此外，他还是一家医疗仪器公司的总裁。Dutia先生在圣路易斯华盛顿大学获得化学工程学士和硕士学位以及政治学学士学位。此外，他还获得了达拉斯大学的工商管理硕士学位。
- Suren Dutia has been a member of the Board of Directors since August 12, 2024. Mr. Dutia has also been a member of the board of directors of Citius Pharma since October 2015. In addition to his role as an outside independent director of Citius Pharma, Mr. Dutia has been serving as director of Flint Rehab and Vahan Inc, since 2016. Mr. Dutia has been involved in fostering entrepreneurship for more than 20 years and served as Senior Fellow of the Ewing Mario Kauffman Foundation from March 2011 to December 2016 and Senior Fellow of Skandalaris Center for Entrepreneurship and Innovation at Washington University, St. Louis from 2010 to 2013. He has served as a member of the advisory board of Center for Digital Transformation, University of California, Irvine since May 2012. From February 2006 to May 2010, Mr. Dutia served as the Chief Executive Officer of TiE, a non profit organization involved in fostering entrepreneurship globally. From February 2011 to May 2013, Mr. Dutia served as a director of LifeProof and from July 2000 to December 2011, he served as a director of Anvita Health. From 1989 to 1998, Mr. Dutia served as the Chief Executive Officer and Chairman of the board of directors of Xscribe Corporation. Prior to his positions with Xscribe Corporation, Mr. Dutia held several positions with Dynatech Corporation, and, in addition, he was the President of a medical instruments company. Mr. Dutia received his B.S. and M.S. degrees in chemical engineering and B.A. in political science from Washington University, St. Louis. In addition, he obtained an M.B.A. from the University of Dallas.
- Carol Webb
-
Carol Webb自2024年8月12日起担任董事会成员。Webb女士自2014年3月17日起担任Citius Pharma的全资子公司Leonard Meron Biosciences，Inc.（“LMB”）的董事，并于2016年3月在LMB被Citius Pharma收购后担任该公司的董事，此后一直担任Citius Pharma的董事会成员。2000年至2005年，她担任强生公司集团董事长。从1987年到2000年，她在Ortho Biotech担任过各种职务，包括总裁、副总裁、执行董事、产品管理和高级产品总监。从1972年到1983年，Webb女士在罗氏实验室担任过多个职位，包括销售代表、销售培训师、产品经理和公共政策经理。Webb女士在鲍灵格林州立大学获得生物学学士学位。
Carol Webb has been a member of the Board of Directors since August 12, 2024. Ms. Webb served as a director of Leonard Meron Biosciences, Inc. ("LMB"), a wholly owned subsidiary of Citius Pharma, beginning March 17, 2014 and, upon LMB's acquisition by the Citius Pharma in March 2016, and has since been a member of the board of directors of Citius Pharma. From 2000 to 2005, she served as Company Group Chairman of Johnson & Johnson. From 1987 to 2000, she served in various capacities at Ortho Biotech, including President, Vice President, Executive Director, Product Management and Senior Product Director. From 1972 to 1983, Ms. Webb worked in various positions at Roche Laboratories, including Sales Representative, Sales Trainer, Product Manager and Manager of Public Policy. Ms. Webb received her B.S. in Biology from Bowling Green State University. - Carol Webb自2024年8月12日起担任董事会成员。Webb女士自2014年3月17日起担任Citius Pharma的全资子公司Leonard Meron Biosciences，Inc.（“LMB”）的董事，并于2016年3月在LMB被Citius Pharma收购后担任该公司的董事，此后一直担任Citius Pharma的董事会成员。2000年至2005年，她担任强生公司集团董事长。从1987年到2000年，她在Ortho Biotech担任过各种职务，包括总裁、副总裁、执行董事、产品管理和高级产品总监。从1972年到1983年，Webb女士在罗氏实验室担任过多个职位，包括销售代表、销售培训师、产品经理和公共政策经理。Webb女士在鲍灵格林州立大学获得生物学学士学位。
- Carol Webb has been a member of the Board of Directors since August 12, 2024. Ms. Webb served as a director of Leonard Meron Biosciences, Inc. ("LMB"), a wholly owned subsidiary of Citius Pharma, beginning March 17, 2014 and, upon LMB's acquisition by the Citius Pharma in March 2016, and has since been a member of the board of directors of Citius Pharma. From 2000 to 2005, she served as Company Group Chairman of Johnson & Johnson. From 1987 to 2000, she served in various capacities at Ortho Biotech, including President, Vice President, Executive Director, Product Management and Senior Product Director. From 1972 to 1983, Ms. Webb worked in various positions at Roche Laboratories, including Sales Representative, Sales Trainer, Product Manager and Manager of Public Policy. Ms. Webb received her B.S. in Biology from Bowling Green State University.
- Eugene Holuka
-
Eugene Holuka自2024年8月12日起担任董事会成员。Holuka博士还自2016年6月起担任Citius Pharma的董事会成员。Holuka医生是一名内科医生，在内科执业约35年。他目前是史坦顿岛大学医院的主治医师，自1991年以来一直在该医院执业。Holuka博士自2011年起还担任Touro整骨医学学院的兼职临床助理教授，目前担任霍夫斯特拉大学Zucker医学院的副教授。从2014年4月到2016年3月公司收购LMB，他是LMB科学顾问委员会成员。Holuka博士于2000年获得埃利斯岛荣誉勋章，自2005年以来一直担任NECO委员会董事会成员。从2000年到2008年，他是论坛儿童基金会的执行委员会成员。
Eugene Holuka has been a member of the Board of Directors since August 12, 2024. Dr. Holuka has also been a member of the board of directors of Citius Pharma since June 2016. Dr. Holuka is an internist and has practiced in internal medicine for approximately 35 years. He is presently an attending physician at the Staten Island University Hospital where he has practiced since 1991. Dr. Holuka has also served as an Adjunct Clinical Assistant Professor at the Touro College of Osteopathic Medicine since 2011 and currently serves as an associate professor at the Zucker School of Medicine at Hofstra University. From April 2014 until the acquisition of LMB by the Company in March 2016, he was a member of the LMB Scientific Advisory Board. Dr. Holuka received the Ellis Island Medal of Honor in 2000 and has served on the NECO Committee Board since 2005. He was an Executive Committee Member on the Forum's Children Foundation from 2000 until 2008. - Eugene Holuka自2024年8月12日起担任董事会成员。Holuka博士还自2016年6月起担任Citius Pharma的董事会成员。Holuka医生是一名内科医生，在内科执业约35年。他目前是史坦顿岛大学医院的主治医师，自1991年以来一直在该医院执业。Holuka博士自2011年起还担任Touro整骨医学学院的兼职临床助理教授，目前担任霍夫斯特拉大学Zucker医学院的副教授。从2014年4月到2016年3月公司收购LMB，他是LMB科学顾问委员会成员。Holuka博士于2000年获得埃利斯岛荣誉勋章，自2005年以来一直担任NECO委员会董事会成员。从2000年到2008年，他是论坛儿童基金会的执行委员会成员。
- Eugene Holuka has been a member of the Board of Directors since August 12, 2024. Dr. Holuka has also been a member of the board of directors of Citius Pharma since June 2016. Dr. Holuka is an internist and has practiced in internal medicine for approximately 35 years. He is presently an attending physician at the Staten Island University Hospital where he has practiced since 1991. Dr. Holuka has also served as an Adjunct Clinical Assistant Professor at the Touro College of Osteopathic Medicine since 2011 and currently serves as an associate professor at the Zucker School of Medicine at Hofstra University. From April 2014 until the acquisition of LMB by the Company in March 2016, he was a member of the LMB Scientific Advisory Board. Dr. Holuka received the Ellis Island Medal of Honor in 2000 and has served on the NECO Committee Board since 2005. He was an Executive Committee Member on the Forum's Children Foundation from 2000 until 2008.
- Dennis M. McGrath
-
Dennis M. McGrath自2024年8月12日起担任董事会成员。McGrath先生还自2023年2月起担任Citius Pharma的董事会成员。自2019年3月起担任多元化商业阶段医疗技术公司PAVmed，Inc.（纳斯达克：PAVM）总裁（曾于2017年3月至2019年3月担任执行副总裁），自2017年3月起担任PAVmed的首席财务官。自Lucid首次公开发行股票完成以来，McGrath先生还担任过Lucid的首席财务官，Lucid是PAVmed的多数股权子公司。在此之前，从2000年到2017年，McGrath先生曾在PhotoMedex，Inc.（前身为纳斯达克：PHMD）担任多个高级职位，该公司是一家全球医疗器械设备和服务制造商和分销商，包括从2011年到2017年担任董事、总裁、首席财务官。在PhotoMedex于2011年12月与Radiancy，Inc进行反向收购之前，他还曾于2009年至2011年担任董事会成员兼首席执行官，并于2000年至2009年担任财务副总裁兼首席财务官。他获得了P.A.T.（费城资本与技术联盟）2011年度投资交易决赛入围者、SmartCEO杂志2012年度Turnaround Company首席执行官奖得主、安永2013年度企业家决赛入围者等荣誉。他在国内和国际并购方面拥有丰富的经验，尤其涉及上市公司收购，包括Surgical Laser Technologies，Inc（前身为纳斯达克：SLTI）、ProCyte Corporation（前身为纳斯达克：PRCY）、LCA Vision，Inc.（前身为纳斯达克：LCAV）和Think New Ideas，Inc.（前身为纳斯达克：THNK）。在加入PhotoMedex之前，他曾在AnswerThink Consulting Group，Inc.（当时，纳斯达克：ANSR，现在，哈克特服务，纳斯达克：HCKT）担任多个高级职位，这是一家商业咨询和技术整合公司，包括在1999年至2000年期间担任AnswerThink Consulting Group，Inc.最大的部门Internet Practice的首席运营官，同时在两家公司合并期间兼任Think New Ideas，Inc.（当时，丨纳斯达克纳斯达克：THNK，现在，丨纳斯达克纳斯达克：HCKT）的代理首席财务官，一家互动营销服务和商业解决方案公司。McGrath先生还曾在1996年至1999年期间担任首席财务官、TriSpan，Inc.的执行副总裁兼董事，TriSpan，Inc.是一家互联网商务解决方案和技术咨询公司，该公司于1999年被AnswerThink Consulting Group，Inc.收购。他在Arthur Andersen & Co.任职期间开始了他的职业生涯，并于1981年成为一名注册会计师，他拥有拉萨尔大学会计学学士学位，最高优等生。他还担任泰勒大学访客委员会和马诺学院董事会成员。
Dennis M. McGrath has been a member of the Board of Directors since August 12, 2024. Mr. McGrath has also been a member of the board of directors of Citius Pharma since February 2023. He has served as the President of PAVmed, Inc. (Nasdaq: PAVM), a diversified commercial stage medical technology company since March 2019 (having served as Executive Vice President from March 2017 to March 2019) and as PAVmed's Chief Financial Officer since March 2017. Mr. McGrath has also served as the Chief Financial Officer of Lucid, PAVmed's majority owned subsidiary since the consummation of Lucid's initial public offering. Previously, from 2000 to 2017 Mr. McGrath served in several senior level positions of PhotoMedex, Inc. (formerly, Nasdaq: PHMD), a global manufacturer and distributor of medical device equipment and services, including from 2011 to 2017 as director, President, and Chief Financial Officer. Prior to PhotoMedex's reverse merger with Radiancy, Inc in December 2011, he also served as a board member and Chief Executive Officer from 2009 to 2011 and served as Vice President of Finance and Chief Financial Officer from 2000 to 2009. He received honors as a P.A.C.T. (Philadelphia Alliance for Capital and Technology) finalist for the 2011 Investment Deal of the Year, award winner for the SmartCEO Magazine 2012 CEO of the Year for Turnaround Company, and finalist for the Ernst & Young 2013 Entrepreneur of the Year. He has extensive experience in mergers and acquisitions, both domestically and internationally, particularly involving public company acquisitions, including Surgical Laser Technologies, Inc, (formerly, Nasdaq: SLTI), ProCyte Corporation (formerly, Nasdaq: PRCY), LCA Vision, Inc. (formerly, Nasdaq: LCAV) and Think New Ideas, Inc. (formerly, Nasdaq: THNK). Prior to PhotoMedex, he served in several senior level positions of AnswerThink Consulting Group, Inc. (then, Nasdaq: ANSR, now, The Hackett Group, Nasdaq: HCKT), a business consulting and technology integration company, including from 1999 to 2000 as Chief Operating Officer of the Internet Practice, the largest division of AnswerThink Consulting Group, Inc., while concurrently during the merger of the companies, serving as the acting Chief Financial Officer of Think New Ideas, Inc. (then, Nasdaq: THNK, now, Nasdaq: HCKT), an interactive marketing services and business solutions company. Mr. McGrath also served from 1996 until 1999 as Chief Financial Officer, Executive Vice President and director of TriSpan, Inc., an internet commerce solutions and technology consulting company, which was acquired by AnswerThink Consulting Group, Inc. in 1999. During his tenure at Arthur Andersen & Co., where he began his career, he became a Certified Public Accountant in 1981 and he holds a B.S., maxima cum laude, in accounting from LaSalle University. He also serves on the Board of Visitors for Taylor University and on Board of Trustees of Manor College. - Dennis M. McGrath自2024年8月12日起担任董事会成员。McGrath先生还自2023年2月起担任Citius Pharma的董事会成员。自2019年3月起担任多元化商业阶段医疗技术公司PAVmed，Inc.（纳斯达克：PAVM）总裁（曾于2017年3月至2019年3月担任执行副总裁），自2017年3月起担任PAVmed的首席财务官。自Lucid首次公开发行股票完成以来，McGrath先生还担任过Lucid的首席财务官，Lucid是PAVmed的多数股权子公司。在此之前，从2000年到2017年，McGrath先生曾在PhotoMedex，Inc.（前身为纳斯达克：PHMD）担任多个高级职位，该公司是一家全球医疗器械设备和服务制造商和分销商，包括从2011年到2017年担任董事、总裁、首席财务官。在PhotoMedex于2011年12月与Radiancy，Inc进行反向收购之前，他还曾于2009年至2011年担任董事会成员兼首席执行官，并于2000年至2009年担任财务副总裁兼首席财务官。他获得了P.A.T.（费城资本与技术联盟）2011年度投资交易决赛入围者、SmartCEO杂志2012年度Turnaround Company首席执行官奖得主、安永2013年度企业家决赛入围者等荣誉。他在国内和国际并购方面拥有丰富的经验，尤其涉及上市公司收购，包括Surgical Laser Technologies，Inc（前身为纳斯达克：SLTI）、ProCyte Corporation（前身为纳斯达克：PRCY）、LCA Vision，Inc.（前身为纳斯达克：LCAV）和Think New Ideas，Inc.（前身为纳斯达克：THNK）。在加入PhotoMedex之前，他曾在AnswerThink Consulting Group，Inc.（当时，纳斯达克：ANSR，现在，哈克特服务，纳斯达克：HCKT）担任多个高级职位，这是一家商业咨询和技术整合公司，包括在1999年至2000年期间担任AnswerThink Consulting Group，Inc.最大的部门Internet Practice的首席运营官，同时在两家公司合并期间兼任Think New Ideas，Inc.（当时，丨纳斯达克纳斯达克：THNK，现在，丨纳斯达克纳斯达克：HCKT）的代理首席财务官，一家互动营销服务和商业解决方案公司。McGrath先生还曾在1996年至1999年期间担任首席财务官、TriSpan，Inc.的执行副总裁兼董事，TriSpan，Inc.是一家互联网商务解决方案和技术咨询公司，该公司于1999年被AnswerThink Consulting Group，Inc.收购。他在Arthur Andersen & Co.任职期间开始了他的职业生涯，并于1981年成为一名注册会计师，他拥有拉萨尔大学会计学学士学位，最高优等生。他还担任泰勒大学访客委员会和马诺学院董事会成员。
- Dennis M. McGrath has been a member of the Board of Directors since August 12, 2024. Mr. McGrath has also been a member of the board of directors of Citius Pharma since February 2023. He has served as the President of PAVmed, Inc. (Nasdaq: PAVM), a diversified commercial stage medical technology company since March 2019 (having served as Executive Vice President from March 2017 to March 2019) and as PAVmed's Chief Financial Officer since March 2017. Mr. McGrath has also served as the Chief Financial Officer of Lucid, PAVmed's majority owned subsidiary since the consummation of Lucid's initial public offering. Previously, from 2000 to 2017 Mr. McGrath served in several senior level positions of PhotoMedex, Inc. (formerly, Nasdaq: PHMD), a global manufacturer and distributor of medical device equipment and services, including from 2011 to 2017 as director, President, and Chief Financial Officer. Prior to PhotoMedex's reverse merger with Radiancy, Inc in December 2011, he also served as a board member and Chief Executive Officer from 2009 to 2011 and served as Vice President of Finance and Chief Financial Officer from 2000 to 2009. He received honors as a P.A.C.T. (Philadelphia Alliance for Capital and Technology) finalist for the 2011 Investment Deal of the Year, award winner for the SmartCEO Magazine 2012 CEO of the Year for Turnaround Company, and finalist for the Ernst & Young 2013 Entrepreneur of the Year. He has extensive experience in mergers and acquisitions, both domestically and internationally, particularly involving public company acquisitions, including Surgical Laser Technologies, Inc, (formerly, Nasdaq: SLTI), ProCyte Corporation (formerly, Nasdaq: PRCY), LCA Vision, Inc. (formerly, Nasdaq: LCAV) and Think New Ideas, Inc. (formerly, Nasdaq: THNK). Prior to PhotoMedex, he served in several senior level positions of AnswerThink Consulting Group, Inc. (then, Nasdaq: ANSR, now, The Hackett Group, Nasdaq: HCKT), a business consulting and technology integration company, including from 1999 to 2000 as Chief Operating Officer of the Internet Practice, the largest division of AnswerThink Consulting Group, Inc., while concurrently during the merger of the companies, serving as the acting Chief Financial Officer of Think New Ideas, Inc. (then, Nasdaq: THNK, now, Nasdaq: HCKT), an interactive marketing services and business solutions company. Mr. McGrath also served from 1996 until 1999 as Chief Financial Officer, Executive Vice President and director of TriSpan, Inc., an internet commerce solutions and technology consulting company, which was acquired by AnswerThink Consulting Group, Inc. in 1999. During his tenure at Arthur Andersen & Co., where he began his career, he became a Certified Public Accountant in 1981 and he holds a B.S., maxima cum laude, in accounting from LaSalle University. He also serves on the Board of Visitors for Taylor University and on Board of Trustees of Manor College.
- Robert J. Smith
-
Robert J. Smith自2024年8月12日起担任董事会成员。自2024年3月以来，史密斯先生还一直是Citius Pharma的董事会成员。过去八年（2016年5月至2024年1月），Smith先生担任辉瑞全球基因治疗业务高级副总裁，负责与罕见病研究单位合作管理和领导基因治疗和罕见病早期商业开发活动。在辉瑞任职期间，Smith先生还曾担任业务发展和联盟管理高级副总裁（2009年10月至2024年1月），领导其全球研发组织以及辉瑞全球所有生物制药业务部门和全球研发组织的业务发展和战略团队，这些业务发展和战略团队分别是辉瑞的全球动物健康、辉瑞的前子公司Capsugel、消费者保健和营养业务部门，以及支持TERM3全球所有生物制药业务部门和全球研发组织的联盟管理职能。Smith先生于2009年从惠氏制药加入辉瑞，紧随辉瑞收购惠氏之后，他担任并购高级副总裁（2008年4月至2009年10月），负责领导和管理惠氏的全球并购集团。在此之前，在惠氏担任全球授权高级副总裁期间，他完成了大量支持惠氏商业和研发部门的交易。Smith先生曾担任私营公司AM Pharma B.V.（观察员）、Bamboo Therapeutics Inc.（2016年1月至2016年8月）、Ignite Immunotherapeutics Inc.（2016年12月至2019年10月）以及Iterum Therapeutics Limited（观察员）（纳斯达克：ITRM）的董事会成员。Smith先生还担任或曾经担任Life Sciences PA –宾夕法尼亚州生物技术协会、Bio NJ –新泽西州生物技术协会（自2021年起）、Duke Margolis Value Based Agreements Advisory Board、再生医学联盟（ARM）（自2018年起）和细胞与基因医学基金会（FCGM）（自2019年起）的成员。他是ARM和FCGM董事会执行委员会成员，并担任ARM董事会治理和运营委员会主席。Smith先生还是Ocugen, Inc.商业顾问委员会、威斯康星州麦迪逊市Venture Investors LLC投资咨询委员会以及弗吉尼亚州夏洛茨维尔Focused Ultrasound Foundation的细胞和基因治疗科学顾问委员会的成员。Smith先生获得了罗切斯特大学神经科学学士学位和纽约州罗切斯特罗切斯特大学William E. Simon工商管理研究生院的金融和企业会计工商管理硕士学位。
Robert J. Smith has been a member of the Board of Directors since August 12, 2024. Mr. Smith has also been a member of the board of directors of Citius Pharma since March 2024. For the past eight years (May 2016 to January 2024), Mr. Smith served as Senior Vice President, Global Gene Therapy Business of Pfizer and was responsible for managing and leading gene therapy and rare disease early commercial development activities in partnership with the rare disease research unit. During his tenure at Pfizer, Mr. Smith also served as Senior Vice President, Business Development and Alliance Management (October 2009 to January 2024) and led its worldwide research and development organization and the business development and strategy teams for Pfizer's global animal health, Capsugel, a former subsidiary of Pfizer, consumer healthcare and nutrition business units, as well as the alliance management function supporting all of Pfizer's global biopharmaceutical business units and the worldwide research and development organization. Mr. Smith joined Pfizer from Wyeth Pharmaceuticals in 2009, following Pfizer's acquisition of Wyeth, where he was Senior Vice President, Mergers and Acquisitions (April 2008 to October 2009) responsible for leading and managing Wyeth's global mergers and acquisitions group. Prior to that, in his role at Wyeth as Senior Vice President of Global Licensing, he completed a wide variety of transactions in support of Wyeth's commercial and research and development divisions. Mr. Smith has served as a member of the board of directors of private companies AM Pharma B.V. (observer), Bamboo Therapeutics Inc. (January 2016 to August 2016), and Ignite Immunotherapeutics Inc. (December 2016 to October 2019), as well as Iterum Therapeutics Limited (observer) (Nasdaq: ITRM). Mr. Smith also serves or has served as a member of Life Sciences PA – the Pennsylvania Biotechnology Association, Bio NJ – the New Jersey State Biotechnology Association (since 2021), the Duke Margolis Value Based Agreements Advisory Board, the Alliance for Regenerative Medicine (ARM) (since 2018) and the Foundation for Cell and Gene Medicine (FCGM) (since 2019). He is a member of the Executive Committees of the ARM and FCGM Board of Directors and serves as the Chairman of the ARM Board's Governance and Operations Committee. Mr. Smith is also a member of the Business Advisory Board of Ocugen, Inc., the Investment Advisory Committee for Venture Investors LLC, Madison, Wisconsin, and the Cell and Gene Therapy Scientific Advisory Board of the Focused Ultrasound Foundation based in Charlottesville, Virginia. Mr. Smith obtained a B.S. in Neuroscience from the University of Rochester and an M.B.A. in Finance and Corporate Accounting from the William E. Simon Graduate School of Business Administration at the University of Rochester, Rochester, New York. - Robert J. Smith自2024年8月12日起担任董事会成员。自2024年3月以来，史密斯先生还一直是Citius Pharma的董事会成员。过去八年（2016年5月至2024年1月），Smith先生担任辉瑞全球基因治疗业务高级副总裁，负责与罕见病研究单位合作管理和领导基因治疗和罕见病早期商业开发活动。在辉瑞任职期间，Smith先生还曾担任业务发展和联盟管理高级副总裁（2009年10月至2024年1月），领导其全球研发组织以及辉瑞全球所有生物制药业务部门和全球研发组织的业务发展和战略团队，这些业务发展和战略团队分别是辉瑞的全球动物健康、辉瑞的前子公司Capsugel、消费者保健和营养业务部门，以及支持TERM3全球所有生物制药业务部门和全球研发组织的联盟管理职能。Smith先生于2009年从惠氏制药加入辉瑞，紧随辉瑞收购惠氏之后，他担任并购高级副总裁（2008年4月至2009年10月），负责领导和管理惠氏的全球并购集团。在此之前，在惠氏担任全球授权高级副总裁期间，他完成了大量支持惠氏商业和研发部门的交易。Smith先生曾担任私营公司AM Pharma B.V.（观察员）、Bamboo Therapeutics Inc.（2016年1月至2016年8月）、Ignite Immunotherapeutics Inc.（2016年12月至2019年10月）以及Iterum Therapeutics Limited（观察员）（纳斯达克：ITRM）的董事会成员。Smith先生还担任或曾经担任Life Sciences PA –宾夕法尼亚州生物技术协会、Bio NJ –新泽西州生物技术协会（自2021年起）、Duke Margolis Value Based Agreements Advisory Board、再生医学联盟（ARM）（自2018年起）和细胞与基因医学基金会（FCGM）（自2019年起）的成员。他是ARM和FCGM董事会执行委员会成员，并担任ARM董事会治理和运营委员会主席。Smith先生还是Ocugen, Inc.商业顾问委员会、威斯康星州麦迪逊市Venture Investors LLC投资咨询委员会以及弗吉尼亚州夏洛茨维尔Focused Ultrasound Foundation的细胞和基因治疗科学顾问委员会的成员。Smith先生获得了罗切斯特大学神经科学学士学位和纽约州罗切斯特罗切斯特大学William E. Simon工商管理研究生院的金融和企业会计工商管理硕士学位。
- Robert J. Smith has been a member of the Board of Directors since August 12, 2024. Mr. Smith has also been a member of the board of directors of Citius Pharma since March 2024. For the past eight years (May 2016 to January 2024), Mr. Smith served as Senior Vice President, Global Gene Therapy Business of Pfizer and was responsible for managing and leading gene therapy and rare disease early commercial development activities in partnership with the rare disease research unit. During his tenure at Pfizer, Mr. Smith also served as Senior Vice President, Business Development and Alliance Management (October 2009 to January 2024) and led its worldwide research and development organization and the business development and strategy teams for Pfizer's global animal health, Capsugel, a former subsidiary of Pfizer, consumer healthcare and nutrition business units, as well as the alliance management function supporting all of Pfizer's global biopharmaceutical business units and the worldwide research and development organization. Mr. Smith joined Pfizer from Wyeth Pharmaceuticals in 2009, following Pfizer's acquisition of Wyeth, where he was Senior Vice President, Mergers and Acquisitions (April 2008 to October 2009) responsible for leading and managing Wyeth's global mergers and acquisitions group. Prior to that, in his role at Wyeth as Senior Vice President of Global Licensing, he completed a wide variety of transactions in support of Wyeth's commercial and research and development divisions. Mr. Smith has served as a member of the board of directors of private companies AM Pharma B.V. (observer), Bamboo Therapeutics Inc. (January 2016 to August 2016), and Ignite Immunotherapeutics Inc. (December 2016 to October 2019), as well as Iterum Therapeutics Limited (observer) (Nasdaq: ITRM). Mr. Smith also serves or has served as a member of Life Sciences PA – the Pennsylvania Biotechnology Association, Bio NJ – the New Jersey State Biotechnology Association (since 2021), the Duke Margolis Value Based Agreements Advisory Board, the Alliance for Regenerative Medicine (ARM) (since 2018) and the Foundation for Cell and Gene Medicine (FCGM) (since 2019). He is a member of the Executive Committees of the ARM and FCGM Board of Directors and serves as the Chairman of the ARM Board's Governance and Operations Committee. Mr. Smith is also a member of the Business Advisory Board of Ocugen, Inc., the Investment Advisory Committee for Venture Investors LLC, Madison, Wisconsin, and the Cell and Gene Therapy Scientific Advisory Board of the Focused Ultrasound Foundation based in Charlottesville, Virginia. Mr. Smith obtained a B.S. in Neuroscience from the University of Rochester and an M.B.A. in Finance and Corporate Accounting from the William E. Simon Graduate School of Business Administration at the University of Rochester, Rochester, New York.
高管简历
中英对照 | 中文 | 英文- Myron Holubiak
Myron Holubiak现任公司秘书和董事会成员，自2024年8月12日起担任该职位。在此之前，他曾担任Citius Oncology Sub，Inc.的秘书和董事，自2022年4月1日开始。Holubiak先生还是Citius Pharma的执行副主席，自2022年5月起担任该职位。他还自2015年10月起担任Citius Pharma董事会成员。从2015年10月到2022年4月，Holubiak先生担任Citius Pharma总裁兼首席执行官。Holubiak先生还担任该公司控股多数的子公司NoveCite的代理首席执行官。Holubiak先生在管理大型和新兴的制药和生命科学公司并为其提供咨询方面拥有丰富的经验。Holubiak先生于1998年12月至2001年8月担任罗氏制药公司（“罗氏”）总裁，该公司是一家以研究为基础的大型制药公司。在此之前，他在19年任期内曾在罗氏担任销售和营销职位。自2002年9月至2016年7月，Holubiak先生在董事会任职，最近两年担任BioScrip，Inc.（“BioScrip”）（纳斯达克：BIOS）的董事会主席。BioScrip是全国领先的输液和家庭护理管理解决方案提供商。自2010年7月起，Holubiak先生担任Assembly Biosciences, Inc.（“Assembly”）（纳斯达克：ASMB）及其前身Ventrus Biosciences，Inc.的董事会成员。Assembly是一家生物制药公司，开发针对乙型肝炎病毒（HBV）、三角型肝炎病毒（HDV）和疱疹病毒感染的创新小分子疗法。此外，Holubiak先生还担任私人控股公司bioAffinity技术公司的董事。2013年3月，Holubiak先生创立了公司的全资子公司LMB，并担任LMB的首席执行官兼总裁至2016年3月。此外，Holubiak先生还在2013年4月至2015年4月期间担任管理式护理学院药房基金会的受托人。Holubiak先生获得了匹兹堡大学的分子生物学和生物物理学学士学位；他接受了哈佛商学院和伦敦大学的高级商业培训；以及约克大学健康经济学中心的健康经济学高级培训。
Myron Holubiak is the current Secretary of the Company and a member of the Board of Directors, a position he has held since August 12, 2024. Prior thereto, he served as Secretary and a director of Citius Oncology Sub, Inc., beginning on April 1, 2022. Mr. Holubiak is also the Executive Vice Chairman of Citius Pharma, a position he has held since May 2022. He has also served as a member of the board of directors of Citius Pharma since October 2015. From October 2015 through April 2022, Mr. Holubiak served as Citius Pharma's President and Chief Executive Officer. Mr. Holubiak also serves as the acting Chief Executive Officer of the company's majority owned subsidiary, NoveCite. Mr. Holubiak has extensive experience in managing and advising large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was the President of Roche Laboratories, Inc. ("Roche"), a major research based pharmaceutical company, from December 1998 to August 2001. Prior to that, he held sales and marketing positions at Roche during his 19 year tenure. From September 2002 to July 2016, Mr. Holubiak served on the board of directors and for the last two years was the Chairman of the board of directors of BioScrip, Inc. ("BioScrip") (Nasdaq: BIOS). BioScrip is a leading national provider of infusion and home care management solutions. Since July 2010, Mr. Holubiak has served as a member of the board of directors of Assembly Biosciences, Inc. ("Assembly") (Nasdaq: ASMB) and its predecessor Ventrus Biosciences, Inc. Assembly is a biopharmaceutical company developing innovative, small molecule therapeutics for hepatitis B virus (HBV), hepatitis delta virus (HDV) and herpes virus infections. Additionally, Mr. Holubiak serves as a director for bioAffinity Technologies Inc., a privately held company. In March 2013, Mr. Holubiak founded LMB, the Company's wholly owned subsidiary, and he served as the Chief Executive Officer and President of LMB until March 2016. In addition, Mr. Holubiak was also a trustee of the Academy of Managed Care Pharmacy Foundation from April 2013 to April 2015. Mr. Holubiak received a B.S. in Molecular Biology and Biophysics from the University of Pittsburgh; he received advanced business training from the Harvard Business School and the University of London; and advanced training in health economics from the University of York's Centre for Health Economics.- Myron Holubiak现任公司秘书和董事会成员，自2024年8月12日起担任该职位。在此之前，他曾担任Citius Oncology Sub，Inc.的秘书和董事，自2022年4月1日开始。Holubiak先生还是Citius Pharma的执行副主席，自2022年5月起担任该职位。他还自2015年10月起担任Citius Pharma董事会成员。从2015年10月到2022年4月，Holubiak先生担任Citius Pharma总裁兼首席执行官。Holubiak先生还担任该公司控股多数的子公司NoveCite的代理首席执行官。Holubiak先生在管理大型和新兴的制药和生命科学公司并为其提供咨询方面拥有丰富的经验。Holubiak先生于1998年12月至2001年8月担任罗氏制药公司（“罗氏”）总裁，该公司是一家以研究为基础的大型制药公司。在此之前，他在19年任期内曾在罗氏担任销售和营销职位。自2002年9月至2016年7月，Holubiak先生在董事会任职，最近两年担任BioScrip，Inc.（“BioScrip”）（纳斯达克：BIOS）的董事会主席。BioScrip是全国领先的输液和家庭护理管理解决方案提供商。自2010年7月起，Holubiak先生担任Assembly Biosciences, Inc.（“Assembly”）（纳斯达克：ASMB）及其前身Ventrus Biosciences，Inc.的董事会成员。Assembly是一家生物制药公司，开发针对乙型肝炎病毒（HBV）、三角型肝炎病毒（HDV）和疱疹病毒感染的创新小分子疗法。此外，Holubiak先生还担任私人控股公司bioAffinity技术公司的董事。2013年3月，Holubiak先生创立了公司的全资子公司LMB，并担任LMB的首席执行官兼总裁至2016年3月。此外，Holubiak先生还在2013年4月至2015年4月期间担任管理式护理学院药房基金会的受托人。Holubiak先生获得了匹兹堡大学的分子生物学和生物物理学学士学位；他接受了哈佛商学院和伦敦大学的高级商业培训；以及约克大学健康经济学中心的健康经济学高级培训。
- Myron Holubiak is the current Secretary of the Company and a member of the Board of Directors, a position he has held since August 12, 2024. Prior thereto, he served as Secretary and a director of Citius Oncology Sub, Inc., beginning on April 1, 2022. Mr. Holubiak is also the Executive Vice Chairman of Citius Pharma, a position he has held since May 2022. He has also served as a member of the board of directors of Citius Pharma since October 2015. From October 2015 through April 2022, Mr. Holubiak served as Citius Pharma's President and Chief Executive Officer. Mr. Holubiak also serves as the acting Chief Executive Officer of the company's majority owned subsidiary, NoveCite. Mr. Holubiak has extensive experience in managing and advising large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was the President of Roche Laboratories, Inc. ("Roche"), a major research based pharmaceutical company, from December 1998 to August 2001. Prior to that, he held sales and marketing positions at Roche during his 19 year tenure. From September 2002 to July 2016, Mr. Holubiak served on the board of directors and for the last two years was the Chairman of the board of directors of BioScrip, Inc. ("BioScrip") (Nasdaq: BIOS). BioScrip is a leading national provider of infusion and home care management solutions. Since July 2010, Mr. Holubiak has served as a member of the board of directors of Assembly Biosciences, Inc. ("Assembly") (Nasdaq: ASMB) and its predecessor Ventrus Biosciences, Inc. Assembly is a biopharmaceutical company developing innovative, small molecule therapeutics for hepatitis B virus (HBV), hepatitis delta virus (HDV) and herpes virus infections. Additionally, Mr. Holubiak serves as a director for bioAffinity Technologies Inc., a privately held company. In March 2013, Mr. Holubiak founded LMB, the Company's wholly owned subsidiary, and he served as the Chief Executive Officer and President of LMB until March 2016. In addition, Mr. Holubiak was also a trustee of the Academy of Managed Care Pharmacy Foundation from April 2013 to April 2015. Mr. Holubiak received a B.S. in Molecular Biology and Biophysics from the University of Pittsburgh; he received advanced business training from the Harvard Business School and the University of London; and advanced training in health economics from the University of York's Centre for Health Economics.
- Leonard Mazur
Leonard Mazur为公司董事长兼首席执行官，自2024年8月12日起担任该职务。在此之前，他曾担任Citius Oncology Sub，Inc.的首席执行官，自2022年4月1日开始。Mazur先生还担任Citius Pharmaceuticals, Inc.（“Citius Pharmaceuticals”）（纳斯达克：CTXR）的执行主席和秘书，并自2014年9月起担任Citius Pharma的董事会成员。2022年5月，Mazur先生成为Citius Pharma的首席执行官。他还担任Citius Pharma的多数股权子公司NoveCite，Inc.（“NoveCite”）的秘书，并为Citius Pharma和NoveCite提供其他指导。自2021年8月起，Mazur先生担任Hillstream BioPharma，Inc.（纳斯达克：HILS）的董事会成员。Mazur先生是Akrimax Pharmaceuticals，LLC（“Akrimax”）的联合创始人和副主席，该公司是一家私营制药公司，专门生产心血管和普通医药产品。Akrimax成立于2008年9月，在收购各大药企药品的同时，成功推出了处方药。2005年1月至2012年5月，Mazur co先生创立并担任Triax Pharmaceuticals LLC（“Triax”）的首席运营官，这是一家生产处方皮肤病药物的专业制药公司。在加入Triax之前，他是Genesis Pharmaceutical，Inc.（“Genesis”）的创始人，并在1995年至2005年期间担任首席执行官。Genesis Pharmaceutical，Inc.（“Genesis”）是一家皮肤病产品公司，通过皮肤科医生办公室营销其产品，并为主要制药公司共同推广产品。2003年，Mazur先生成功地将Genesis出售给了领先的制药公司Pierre Fabre。Mazur先生在麦蒂斯制药担任执行副总裁、ICN Pharmaceuticals，Inc.担任销售与营销副总裁、Knoll Pharma（巴斯夫的一个部门）和Cooper Laboratories，Inc.期间拥有丰富的销售、营销和业务发展经验。Mazur先生是Manor College的董事会成员，是埃利斯岛荣誉勋章的获得者，之前曾是公司的全资子公司Leonard Meron Biosciences，Inc.（“LMB”）的董事会主席。马祖尔先生在天普大学获得了学士和工商管理硕士学位，并曾在美国海军陆战队预备队服役。
Leonard Mazur is the Chairman and Chief Executive Officer of the Company, a position he has held since August 12, 2024. Prior thereto, he served as the Chief Executive Officer of Citius Oncology Sub, Inc., beginning on April 1, 2022. Mr. Mazur also serves as the Executive Chairman and Secretary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR) and has been a member of the board of directors of Citius Pharma since September 2014. In May 2022, Mr. Mazur became the Chief Executive Officer of Citius Pharma. He also serves as the Secretary of Citius Pharma's majority owned subsidiary, NoveCite, Inc. ("NoveCite"), and provides other guidance to Citius Pharma and NoveCite. Since August 2021, Mr. Mazur has served on the board of directors of Hillstream BioPharma, Inc. (Nasdaq: HILS). Mr. Mazur is the co founder and Vice Chairman of Akrimax Pharmaceuticals, LLC ("Akrimax"), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Akrimax was founded in September 2008 and has successfully launched prescription drugs while acquiring drugs from major pharmaceutical companies. From January 2005 to May 2012, Mr. Mazur co founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC ("Triax"), a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder and, from 1995 to 2005, Chief Executive Officer of Genesis Pharmaceutical, Inc. ("Genesis"), a dermatological products company that marketed its products through dermatologists' offices as well as co promoting products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company. Mr. Mazur has extensive sales, marketing and business development experience from his tenures at Medicis Pharmaceutical Corporation as Executive Vice President, ICN Pharmaceuticals, Inc. as Vice President, Sales & Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc. Mr. Mazur is a member of the Board of Trustees of Manor College, is a recipient of the Ellis Island Medal of Honor and was previously the Chairman of the board of directors of Leonard Meron Biosciences, Inc. ("LMB"), the Company's wholly owned subsidiary. Mr. Mazur received both his B.A. and M.B.A. from Temple University and has served in the U.S. Marine Corps Reserves.- Leonard Mazur为公司董事长兼首席执行官，自2024年8月12日起担任该职务。在此之前，他曾担任Citius Oncology Sub，Inc.的首席执行官，自2022年4月1日开始。Mazur先生还担任Citius Pharmaceuticals, Inc.（“Citius Pharmaceuticals”）（纳斯达克：CTXR）的执行主席和秘书，并自2014年9月起担任Citius Pharma的董事会成员。2022年5月，Mazur先生成为Citius Pharma的首席执行官。他还担任Citius Pharma的多数股权子公司NoveCite，Inc.（“NoveCite”）的秘书，并为Citius Pharma和NoveCite提供其他指导。自2021年8月起，Mazur先生担任Hillstream BioPharma，Inc.（纳斯达克：HILS）的董事会成员。Mazur先生是Akrimax Pharmaceuticals，LLC（“Akrimax”）的联合创始人和副主席，该公司是一家私营制药公司，专门生产心血管和普通医药产品。Akrimax成立于2008年9月，在收购各大药企药品的同时，成功推出了处方药。2005年1月至2012年5月，Mazur co先生创立并担任Triax Pharmaceuticals LLC（“Triax”）的首席运营官，这是一家生产处方皮肤病药物的专业制药公司。在加入Triax之前，他是Genesis Pharmaceutical，Inc.（“Genesis”）的创始人，并在1995年至2005年期间担任首席执行官。Genesis Pharmaceutical，Inc.（“Genesis”）是一家皮肤病产品公司，通过皮肤科医生办公室营销其产品，并为主要制药公司共同推广产品。2003年，Mazur先生成功地将Genesis出售给了领先的制药公司Pierre Fabre。Mazur先生在麦蒂斯制药担任执行副总裁、ICN Pharmaceuticals，Inc.担任销售与营销副总裁、Knoll Pharma（巴斯夫的一个部门）和Cooper Laboratories，Inc.期间拥有丰富的销售、营销和业务发展经验。Mazur先生是Manor College的董事会成员，是埃利斯岛荣誉勋章的获得者，之前曾是公司的全资子公司Leonard Meron Biosciences，Inc.（“LMB”）的董事会主席。马祖尔先生在天普大学获得了学士和工商管理硕士学位，并曾在美国海军陆战队预备队服役。
- Leonard Mazur is the Chairman and Chief Executive Officer of the Company, a position he has held since August 12, 2024. Prior thereto, he served as the Chief Executive Officer of Citius Oncology Sub, Inc., beginning on April 1, 2022. Mr. Mazur also serves as the Executive Chairman and Secretary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR) and has been a member of the board of directors of Citius Pharma since September 2014. In May 2022, Mr. Mazur became the Chief Executive Officer of Citius Pharma. He also serves as the Secretary of Citius Pharma's majority owned subsidiary, NoveCite, Inc. ("NoveCite"), and provides other guidance to Citius Pharma and NoveCite. Since August 2021, Mr. Mazur has served on the board of directors of Hillstream BioPharma, Inc. (Nasdaq: HILS). Mr. Mazur is the co founder and Vice Chairman of Akrimax Pharmaceuticals, LLC ("Akrimax"), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Akrimax was founded in September 2008 and has successfully launched prescription drugs while acquiring drugs from major pharmaceutical companies. From January 2005 to May 2012, Mr. Mazur co founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC ("Triax"), a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder and, from 1995 to 2005, Chief Executive Officer of Genesis Pharmaceutical, Inc. ("Genesis"), a dermatological products company that marketed its products through dermatologists' offices as well as co promoting products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company. Mr. Mazur has extensive sales, marketing and business development experience from his tenures at Medicis Pharmaceutical Corporation as Executive Vice President, ICN Pharmaceuticals, Inc. as Vice President, Sales & Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc. Mr. Mazur is a member of the Board of Trustees of Manor College, is a recipient of the Ellis Island Medal of Honor and was previously the Chairman of the board of directors of Leonard Meron Biosciences, Inc. ("LMB"), the Company's wholly owned subsidiary. Mr. Mazur received both his B.A. and M.B.A. from Temple University and has served in the U.S. Marine Corps Reserves.
- Jaime Bartushak
Jaime Bartushak于2014年4月1日起担任Citius Pharma的全资子公司Leonard Meron Biosciences，Inc.（“LMB”）的首席财务官，任期至2017年11月。2017年11月，因Citius Pharma收购LMB，成为Citius Pharma的首席财务官。2022年11月，被任命为Citius Pharma首席商务官。Bartushak先生于2024年8月成为Citius Oncology，Inc.的首席财务官。Bartushak先生是一位经验丰富的早期制药公司财务专业人士，拥有超过20年的公司财务、业务发展、重组、战略规划经验。Bartushak先生是2014年LMB的创始人之一，在其启动以及获得初始投资资本方面发挥了重要作用。2014年，在任职于LMB之前，Bartushak先生帮助牵头将PreCision Dermatology，Inc.出售给Valeant Pharmaceuticals International，Inc.。
Jaime Bartushak served as Chief Financial Officer of Leonard Meron Biosciences, Inc. ("LMB"), a wholly owned subsidiary of Citius Pharma from April 1, 2014, until November 2017. In November 2017, he became the Chief Financial Officer of Citius Pharma upon the acquisition of LMB by Citius Pharma. In November 2022, he was appointed Chief Business Officer of Citius Pharma. Mr. Bartushak became Citius Oncology, Inc.'s Chief Financial Officer in August 2024. Mr. Bartushak is an experienced finance professional for early stage pharmaceutical companies, and has over 20 years of corporate finance, business development, restructuring, and strategic planning experience. Mr. Bartushak was one of the founders of LMB in 2014 and was instrumental in its startup as well as in obtaining initial investment capital. In 2014, prior to his work at LMB, Mr. Bartushak helped lead the sale of PreCision Dermatology, Inc. to Valeant Pharmaceuticals International, Inc.- Jaime Bartushak于2014年4月1日起担任Citius Pharma的全资子公司Leonard Meron Biosciences，Inc.（“LMB”）的首席财务官，任期至2017年11月。2017年11月，因Citius Pharma收购LMB，成为Citius Pharma的首席财务官。2022年11月，被任命为Citius Pharma首席商务官。Bartushak先生于2024年8月成为Citius Oncology，Inc.的首席财务官。Bartushak先生是一位经验丰富的早期制药公司财务专业人士，拥有超过20年的公司财务、业务发展、重组、战略规划经验。Bartushak先生是2014年LMB的创始人之一，在其启动以及获得初始投资资本方面发挥了重要作用。2014年，在任职于LMB之前，Bartushak先生帮助牵头将PreCision Dermatology，Inc.出售给Valeant Pharmaceuticals International，Inc.。
- Jaime Bartushak served as Chief Financial Officer of Leonard Meron Biosciences, Inc. ("LMB"), a wholly owned subsidiary of Citius Pharma from April 1, 2014, until November 2017. In November 2017, he became the Chief Financial Officer of Citius Pharma upon the acquisition of LMB by Citius Pharma. In November 2022, he was appointed Chief Business Officer of Citius Pharma. Mr. Bartushak became Citius Oncology, Inc.'s Chief Financial Officer in August 2024. Mr. Bartushak is an experienced finance professional for early stage pharmaceutical companies, and has over 20 years of corporate finance, business development, restructuring, and strategic planning experience. Mr. Bartushak was one of the founders of LMB in 2014 and was instrumental in its startup as well as in obtaining initial investment capital. In 2014, prior to his work at LMB, Mr. Bartushak helped lead the sale of PreCision Dermatology, Inc. to Valeant Pharmaceuticals International, Inc.
- Myron S. Czuczman
Myron S. Czuczman于2020年7月加入Citius Pharma，担任首席医疗官。他于2024年8月成为该公司的首席医疗官。在任职于Citius Pharma之前，Czuczman博士曾担任全球临床研发副总裁，以及新基医药公司淋巴瘤/CLL治疗领域负责人，并于2015年6月至2020年1月担任该职位。在从事制药行业工作之前，Czuczman博士在位于纽约州布法罗的NCI指定综合癌症中心Roswell Park Cancer Institute行医了二十多年，在那里他担任了淋巴瘤/骨髓瘤服务的负责人和淋巴瘤转化研究实验室的负责人。除了广泛的出版记录、在国家和国际研究组织的成员和领导角色，以及为数十家制药公司提供咨询和咨询服务外，Czuczman博士还获得了纽约州立大学布法罗医学院和生物医学科学学院的终身医学教授和罗斯威尔公园综合癌症中心的肿瘤学教授的职位。Czuczman博士以优异成绩从匹兹堡大学生物化学专业毕业后，获得了宾夕法尼亚州立大学医学院的医学学位。他在威尔康乃尔北岸大学/MSKCC项目完成了内科住院医师培训，随后在纽约市纪念斯隆凯特琳癌症中心完成了医学肿瘤学/血液学研究金培训。
Myron S. Czuczman joined Citius Pharma as Chief Medical Officer in July 2020. He became the company's Chief Medical Officer in August 2024. Prior to his employment with Citius Pharma, Dr. Czuczman was Vice President, Global Clinical Research and Development, Therapeutic Area Head of Lymphoma/CLL at Celgene Corporation, a position he held from June 2015 to January 2020. Prior to working in the pharmaceutical industry, Dr. Czuczman practiced medicine for over two decades at Roswell Park Cancer Institute, an NCI designated comprehensive cancer center in Buffalo, NY, where he served as chief of the Lymphoma/Myeloma Service and head of the Lymphoma Translational Research Laboratory. In addition to his extensive publications record, membership and leadership roles on national and international research organizations, and consulting and advisory to dozens of pharma companies, Dr. Czuczman also attained the positions of tenured Professor of Medicine at the State University of New York at Buffalo School of Medicine and Biomedical Sciences and Professor of Oncology at Roswell Park Comprehensive Cancer Center. Dr. Czuczman received his medical degree from the Pennsylvania State University College of Medicine after graduating magna cum laude in Biochemistry from the University of Pittsburgh. He completed his Internal Medicine residency training at Weill Cornell North Shore University/MSKCC Program, followed by Medical Oncology/Hematology fellowship training at Memorial Sloan Kettering Cancer Center in New York City.- Myron S. Czuczman于2020年7月加入Citius Pharma，担任首席医疗官。他于2024年8月成为该公司的首席医疗官。在任职于Citius Pharma之前，Czuczman博士曾担任全球临床研发副总裁，以及新基医药公司淋巴瘤/CLL治疗领域负责人，并于2015年6月至2020年1月担任该职位。在从事制药行业工作之前，Czuczman博士在位于纽约州布法罗的NCI指定综合癌症中心Roswell Park Cancer Institute行医了二十多年，在那里他担任了淋巴瘤/骨髓瘤服务的负责人和淋巴瘤转化研究实验室的负责人。除了广泛的出版记录、在国家和国际研究组织的成员和领导角色，以及为数十家制药公司提供咨询和咨询服务外，Czuczman博士还获得了纽约州立大学布法罗医学院和生物医学科学学院的终身医学教授和罗斯威尔公园综合癌症中心的肿瘤学教授的职位。Czuczman博士以优异成绩从匹兹堡大学生物化学专业毕业后，获得了宾夕法尼亚州立大学医学院的医学学位。他在威尔康乃尔北岸大学/MSKCC项目完成了内科住院医师培训，随后在纽约市纪念斯隆凯特琳癌症中心完成了医学肿瘤学/血液学研究金培训。
- Myron S. Czuczman joined Citius Pharma as Chief Medical Officer in July 2020. He became the company's Chief Medical Officer in August 2024. Prior to his employment with Citius Pharma, Dr. Czuczman was Vice President, Global Clinical Research and Development, Therapeutic Area Head of Lymphoma/CLL at Celgene Corporation, a position he held from June 2015 to January 2020. Prior to working in the pharmaceutical industry, Dr. Czuczman practiced medicine for over two decades at Roswell Park Cancer Institute, an NCI designated comprehensive cancer center in Buffalo, NY, where he served as chief of the Lymphoma/Myeloma Service and head of the Lymphoma Translational Research Laboratory. In addition to his extensive publications record, membership and leadership roles on national and international research organizations, and consulting and advisory to dozens of pharma companies, Dr. Czuczman also attained the positions of tenured Professor of Medicine at the State University of New York at Buffalo School of Medicine and Biomedical Sciences and Professor of Oncology at Roswell Park Comprehensive Cancer Center. Dr. Czuczman received his medical degree from the Pennsylvania State University College of Medicine after graduating magna cum laude in Biochemistry from the University of Pittsburgh. He completed his Internal Medicine residency training at Weill Cornell North Shore University/MSKCC Program, followed by Medical Oncology/Hematology fellowship training at Memorial Sloan Kettering Cancer Center in New York City.